Evaluation of Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis Subjects Without an F508del Mutation
Clinical trial NCT05274269 · COMPLETED
Trial details
- NCT number
- NCT05274269
- Sponsor
- Vertex Pharmaceuticals Incorporated
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-05-09
- Primary completion
- 2023-07-05
- Enrollment
- 307
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.